Advanced search
Publication Cover
Journal of Medical Economics Volume 5, 2002 - Issue 1-4
Submit an article Journal homepage
299
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Introduction of escitalopram, a new SSRI in Finland: comparison of cost-effectiveness between the other SSRIs and SNRI for the treatment of depression and estimation of the budgetary impact

Clément François International Department of Health-Economy, Epidemiology and Pricing, Lundbeck A/S, Paris, FranceCorrespondence[email protected]
,
Harri Sintonen Department of Public Health, University of Helsinki, Finland
&
Mondher Toumi International Department of Health-Economy, Epidemiology and Pricing, Lundbeck A/S, Paris, France
Pages 91-107 | Accepted 25 Jul 2002, Published online: 02 Dec 2008

Citations (18)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Feng Xie, Nicolas Despiegel, Natalya Danchenko & Karina Hansen. (2009) Cost effectiveness analysis of escitalopram compared to venlafaxine and fluvoxamine in treatment of major depressive disorder. International Journal of Psychiatry in Clinical Practice 13:1, pages 59-69.
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Jan Sørensen, Kurt B. Stage, Niels Damsbo, Agathe Le Lay & Michiel E. Hemels. (2007) A Danish cost-effectiveness model of escitalopram in comparison with citalopram and venlafaxine as first-line treatments for major depressive disorder in primary care. Nordic Journal of Psychiatry 61:2, pages 100-108.
Read now

Articles from other publishers (15)

Spyros Kolovos, Judith E. Bosmans, Heleen Riper, Karine Chevreul, Veerle M. H. Coupé & Maurits W. van Tulder. (2017) Model-Based Economic Evaluation of Treatments for Depression: A Systematic Literature Review. PharmacoEconomics - Open 1:3, pages 149-165.
Crossref
Hossein Haji Ali Afzali, Jonathan Karnon & Jodi Gray. (2011) A proposed model for economic evaluations of major depressive disorder. The European Journal of Health Economics 13:4, pages 501-510.
Crossref
Hossein Haji Ali Afzali, Jonathan Karnon & Jodi Gray. (2012) A Critical Review of Model-Based Economic Studies of Depression. PharmacoEconomics 30:6, pages 461-482.
Crossref
Mark J.C. Nuijten, Mélanie Brignone, Florence Marteau, Johan A. den Boer & Erik Hoencamp. (2012) Cost-Effectiveness of Escitalopram in Major Depressive Disorder in the Dutch Health Care Setting. Clinical Therapeutics 34:6, pages 1364-1378.
Crossref
Göran Nordström, Natalya Danchenko, Nicolas Despiegel & Florence Marteau. (2012) Cost-Effectiveness Evaluation in Sweden of Escitalopram Compared with Venlafaxine Extended-Release as First-Line Treatment in Major Depressive Disorder. Value in Health 15:2, pages 231-239.
Crossref
P. M. Llorca & J.-L. Fernandez. (2007) Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. International Journal of Clinical Practice 61:4, pages 702-710.
Crossref
María Velasco, Luis Salvador, Carmelo Juárez & Fernando Antoñanzas. (2013) Análisis de coste-efectividad de escitalopram comparado con citalopram en el tratamiento de pacientes con depresión mayor grave. PharmacoEconomics Spanish Research Articles 3:2, pages 63-73.
Crossref
David Murdoch & Susan J Keam. (2006) Spotlight on Escitalopram in the Management of Major Depressive Disorder1. CNS Drugs 20:2, pages 167-170.
Crossref
Jos??-Luis Fernandez, Stuart Montgomery & Cl??ment Francois. (2005) Evaluation of the Cost Effectiveness of Escitalopram versus Venlafaxine XR in Major Depressive Disorder. PharmacoEconomics 23:2, pages 155-167.
Crossref
David Murdoch & Susan J Keam. (2005) Escitalopram. Drugs 65:16, pages 2379-2404.
Crossref
Koen Demyttenaere, Michiel E.H. Hemels, Joumana Hudry & Lieven Annemans. (2005) A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clinical Therapeutics 27:1, pages 111-124.
Crossref
Michiel EH Hemels, Siegfried Kasper, Evelyn Walter & Thomas R Einarson. (2004) Cost-Effectiveness of Escitalopram versus Citalopram in the Treatment of Severe Depression. Annals of Pharmacotherapy 38:6, pages 954-960.
Crossref
Patrick W Sullivan, Robert Valuck, Joseph Saseen & Holly M MacFall. (2004) A Comparison of the Direct Costs and Cost Effectiveness of Serotonin Reuptake Inhibitors and Associated Adverse Drug Reactions. CNS Drugs 18:13, pages 911-932.
Crossref
Katherine F Croom & Greg L Plosker. (2004) Spotlight on the Pharmacoeconomics of Escitalopram in Depression1. CNS Drugs 18:7, pages 469-473.
Crossref
Katherine F Croom & Greg L Plosker. (2003) Escitalopram. PharmacoEconomics 21:16, pages 1185-1209.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.